Assessment of the abuse liability of ABT-288, a novel histamine H 3 receptor antagonist

Psychopharmacology

Volumn 228, Issue 2, 2013, Pages 187-197

  Hudzik, Thomas J ^a   Basso, Ana ^a   Boyce Rustay, Janel M ^a   Bracken, William ^a   Browman, Kaitlin E ^a   Drescher, Karla ^a   Esbenshade, Timothy A ^a   Loberg, Lise I ^a   Lynch III, James J ^a   Brioni, Jorge D ^a  

^a ABBVIE INC   (United States)

Author keywords

ABT 288; Abuse liability assessment; H3 receptor antagonists; Stimulant effects

Indexed keywords

ABT 288; AMPHETAMINE; CAFFEINE; CHLORPROMAZINE; HISTAMINE H3 RECEPTOR ANTAGONIST;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BODY TEMPERATURE; CONTROLLED STUDY; DEFECATION; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SELF ADMINISTRATION; DRUG SENSITIZATION; GRIP STRENGTH; HYPERACTIVITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RAT; REARING; REINFORCEMENT; STIMULUS RESPONSE;

ANIMALS; COCAINE; DEXTROAMPHETAMINE; DISCRIMINATION LEARNING; DRUG ADMINISTRATION SCHEDULE; HISTAMINE H3 ANTAGONISTS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PYRIDAZINES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; REINFORCEMENT SCHEDULE; SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 84879982522     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3027-7     Document Type: Article

References (27)

1. 3) of histamine receptor. Nature 302:832-837
2. 3-receptors. Neuroscience 15:553-562
3. Bakker RA, Timmerman H, Leurs R (2002) Histamine receptors: specific ligands, receptor biochemistry, and signal transduction. Clin Allergy Immunol 17:27-64
4. 3 antagonist. Br J Pharmacol 143(5):649-661
5. Boissier JR, Simon P (1965) Action de la caféine sur la motilité spontanée de la souris. Arch Int Pharmacodyn Ther 158:212-221
6. 3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther 336:38-46
7. Brown RE, Stevens DR, Haas HL (2001) The physiology of brain histamine. Prog Neurobiol 63:637-672
8. 3 receptors in rodent skin, dorsal root ganglia, superior cervical ganglia, and spinal cord: potential antinociceptive targets. Pain 129:76-92
9. 3 receptor antagonists reach out for the clinic. Drug Disc Today 10(23):1613-1627
10. 3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. Eur J Pharmacol 259(2):107-114
11. 3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity. Biochem Pharmacol 73(8):1243-1255
12. 3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol Interv 6:77-88
13. 3 receptor antagonist with drug-like properties. J Pharmacol Exp Ther 313:165-175
14. 3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 154:1166-1181
15. 3 receptor antagonist. J Pharmacol Exp Ther 343(1):233-245
16. Fox GB, Pan JB, Esbenshade TA, Bennani YL, Black LA, Faghih R et al (2002) Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res 131:151-161
17. 3 receptor antagonist. J Pharmacol Exp Ther 313:176-190
18. 3 receptor antagonist 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl) oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats. J Pharmacol Exp Ther 332:164-172
19. Koob G, Volkow N (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217-238
20. 3 receptor drugs. Nat Rev Drug Discov 4:107-120
21. 3) visualized in the brain of human and non-human primates. Brain Res 526:322-327
22. 3 receptor on sleep and wakefulness. Eur J Pharmacol 205:283-287
23. Moser VC (2000) The functional observational battery in adult and developing rats. Neurotoxicology 21(6):989-996
24. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 25(12):618-625
25. 3 receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J Pharmacol Exp Ther 340:124-133
26. Robinson TE, Becker JB (1986) Enduring changes in behavior produced by chronic amphetamine administration: a review and animal models of amphetamine psychosis. Brain Res Rev 396(2):157-198
27. 3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs 26(5):421-434